Acute Coronary Syndrome
| Product Code | GIA01427 |
| Publication Date | April 2010 |
| Publisher | Global Industry Analysts |
| Product Type | Report |
| Pages | 752 |
| ISBN Number | not applicable |
Acute Coronary Syndrome
This report analyzes the global market for Acute Coronary Syndrome Therapeutics in US$ Million. Annual estimates and forecasts are provided for the period 2006 through 2015. The report profiles 60 companies including Abbott Laboratories Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Inverness Medical Innovations, Inc., Merck & Co., Inc., Medicure Inc., Novartis AG, Pfizer, Inc., Wyeth, Sanofi-Aventis SA, Schering-Plough Corp., Siemens Healthcare Diagnostics, Inc., Takeda Pharmaceutical Company Limited, and The Medicines Company. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Contents
- I.Introduction, Methodology & Product Definitions
- Study Reliability and Reporting Limitations
- Disclaimers
- Data interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
- II. Executive Summary
- 1.Industry Overview
- Acute Coronary Syndrome – a Primer
- Table 1: World Recent Past, Current & Future Analysis for Acute Coronary Syndrome therapeutics Market - Annual Revenues in Us$ Million for Years 2006 Through 2015 (Includes Corresponding Graph/Chart)
- Global Acs Drugs Market Scenario
- Table 2: Leading Acs Drugs with Global Sales Revenues (In Us$ Billion) for the Year 2008 (Includes Corresponding Graph/Chart)
- Table 3: Select Leading Myocardial infarction Drugs Worldwide: Value Sales for 2007 and 2008 in Us$ Million (Includes Corresponding Graph/Chart)
- Table 4: Select Leading Coronary Artery Disease/ Atherosclerosis Drugs Worldwide: Value Sales for 2007 and 2008 in Us$ Million (Includes Corresponding Graph/Chart)
- Table 5: Select Leading Angina Drugs Worldwide: Value Sales for 2007 and 2008 in Us$ Million (Includes Corresponding Graph/Chart)
- Table 6: Estimated Number of Products Available for Select Acs indications (Includes Corresponding Graph/Chart)
- Key Market Drivers and Constraints
- Antithrombotics – the Driving force in Future
- Combination Products
- Drug Delivery Technologies
- Fast and Accurate Diagnosis – Reduce Unnecessary Healthcare Costs
- Patent Expiry of Best Selling Products: a Key Concern for the industry
- List of Leading Cardiovascular Drugs On the Verse of Patent Expiry
- Lack of Product Differentiation
- Fewer Product introductions
- Market Characteristics
- United States and Europe – Far Ahead and Far More Powerful
- Anticoagulants – Remarkable Drug Development Potential
- Anticoagulants to Lose Acs indications to Antiplatelets
- Novel Anticoagulants to Drive Atrial Fibrillation Drug Market
- Protein therapy Research Promises Cardiovascular Disease Treatment
- Future Directions: Shape of Things to Come
- Table 7: Estimated Number of Pipeline Products by Select Acs indication (Includes Corresponding Graph/Chart)
- Table 8: Estimated Number of Candidates in Development Phase by Select Acs indication (Includes Corresponding Graph/Chart)
- List of Cardiovascular (Including Acs) Pipeline Products in Phase Iii Development (As of March 2007)
- List of Cardiovascular (Including Acs) Pipeline Products in Phase Ii Development (As of March 2007)
- List of Cardiovascular (Including Acs) Pipeline Products in Phase I Development (As of March 2007)
- List of Cardiovascular (Including Acs) Pipeline Products in Pre-Clinical Development (As of March 2007)
- Pharmaceutical industry: a Review of the Current Scenario
- Industry Framework
- Consolidation Gets Underway
- Patent Expiries Giving Way to Generic Drugs
- Developing Countries Hold the Key to Future Growth
- Table 9: World Pharmaceutical industry (2007): Bric Nations (Brazil, Russia, India and China), & United States Ranked by Percentage Growth (Includes Corresponding Graph/Chart)
- Impact of the Recession: An Unequivocal Review
- 2.Disease Overview
- Definition and Pathophysiology
- Cardiac Circulation and Conduction
- Acute Coronary Syndrome – a Definition
- Underlying Cause of Acs
- Unstable Angina
- Causes and Symptoms
- Treatment Options
- Myocardial infarction (Mi)
- Non-St-Segment Elevated Myocardial infarction (Nstemi)
- St-Segment Elevated Myocardial infarction (Stemi)
- Chain Reaction After An Event of Mi
- Action Plan After An Event of Mi
- Causes and Symptoms
- Drug Treatment Options
- Epidemiology
- Cardiovascular Diseases
- Table 10: Region-Wise incidence and Prevalence of Cardiovascular Diseases in 2006 (Includes Corresponding Graph/Chart)
- Factors Responsible for Coronary Diseases
- Uncontrollable Risk Factors
- Ageing Global Population
- Table 11: World Demographic Trends: People Over 65 as a Percentage of total Population by Geographic Region- Us, Canada, Japan, Europe, asia-Pacific, and Latin America for Years 2000, 2008, 2010, and 2020 (Includes Corresponding Graph/Chart)
- Heredity
- Gender
- Diabetes
- Controllable Risk Factors
- High Blood Cholesterol
- Hdl Cholesterol
- Hdl Cholesterol Levels and Potential Risk of Cardiovascular Disease
- Ldl Cholesterol
- Ldl Cholesterol Levels and Potential Risk of Cardiovascular Disease
- Triglyceride Levels
- Triglyceride Level and Potential Risk of Cardiovascular Disease
- Smoking
- Changing Habits and Lifestyle
- High Blood Pressure
- Causative Risk Factors
- Stress and Anger
- Obesity
- Disease investigation and Diagnosis
- Ecg
- Exercise Ecg (Ecg Stress Testing)
- Test Procedure and Precautions
- Blood Tests (for the Presence of Cardiac Biomarkers)
- Myocardial infarction Cardiac Biomarkers - Benefits and Limitations
- C-Reactive Protein
- Necessity of a Cardiac Marker assay Test
- How It Works?
- Need for Early Detection Markers
- Strong Demand for Risk assessment Markers
- Invasive Imaging Tests
- Coronary Angiography (Or Cardiac Angiography)
- Test Procedure and Results
- Intravascular Ultrasound (Ivus)
- Test Procedure and Results
- Medication Strategies
- Anti-Ischemic Agents
- Nitrates
- Description On Some of the Nitrate Drugs for Acute Coronary Syndrome
- Usage of Nitrates in Acs indications
- Unstable Angina (Ua)
- Acute Myocardial infarction (Ami)
- ( Blockers
- List of indications for Select Beta-Blocker Drugs
- Calcium Channel Blockers
- List of indications for Select Calcium Channel Blockers
- Ace and Ace Ii inhibitor Drugs
- Angiotensin Converting Enzyme (Ace) inhibitors
- List of Different Types of Ace inhibitors and Products
- Angiotensin Ii Receptor Antagonists (Ace Ii Or Sartans)
- List of Different Types of Angiotensin Ii Receptor Antagonists and Products
- Cholesterol Reducing Drugs
- Statins Lead the Way
- Emerging Leaders
- Table 12: Leading Cholesterol Reducing Drugs Worldwide: Sales for the Years 2004 Through 2008 for Lipitor, Crestor and Vytorin (In Us$ Billion) (Includes Corresponding Graph/Chart)
- Lack of Product Differentiation Mars Prospects
- Zocor – the First Statin to Switch to Otc
- Patent Expiries of Leading Cholesterol Reducers: 2009 and Beyond
- Anticoagulants
- Anticoagulant Drug Classes
- Oral Anticoagulants
- Warfarin
- Coumadin
- Injectable Anticoagulants
- Heparin
- Unfractionated Heparin
- Low Molecular Weight Heparin (Lmwh)
- A Snapshot of Available Anticoagulant therapies
- Antiplatelet Agents
- List of indications for Select Antiplatelet Drugs
- Thrombolytics
- Key indications Relating to Acs
- Others
- Aspirin
- Oxygen Supply
- Pain Reliving Agents
- Revascularization Procedures
- Invasive Treatments
- Bypass Surgery
- Percutaneous Transluminal Coronary Angioplasty (Balloon Angioplasty)
- Coronary Stents
- Drug Eluting Stents Steal the Show
- Applications of Coronary Stents
- Key Stents Delivery Platforms by Select Company
- Coronary Stents – Leading Players
- Table 13: Leading Players in the Global Coronary Stents Market (2006-2008) – Percentage Breakdown by Revenues for Boston Scientific, Johnson & Johnson, Abbott, Medtronic, and Others (Includes Corresponding Graph/Chart)
- Bare Metal Stents – Leading Players
- Table 14: Leading Players in the Global Bare Metal Stents Market (2006-2008) – Percentage Breakdown by Revenues for Abbott, Johnson & Johnson, Boston Scientific, Medtronic, and Others (Includes Corresponding Graph/Chart)
- Drug-Eluting Stents – Leading Players
- Table 15: Leading Players in the Global Drug-Eluting Stents Market (2006-2008) – Percentage Breakdown by Revenues for Boston Scientific, Johnson & Johnson, Abbott, and Medtronic (Includes Corresponding Graph/Chart)
- Cell Transplantation – An Emerging Procedure for Chronic Heart Ailments
- 3.Regional Market Overview
- The United States
- Cardiovascular Diseases in the Us: a Review
- Table 16: the US Disease Statistics for Coronary Heart Disease (Chd) & Myocardial infarction (Mi) (Includes Corresponding Graph/Chart)
- Aha Statistics for Coronary Heart Disease
- Table 17: the US Prevalence of Coronary Heart Disease (Chd) as a Percentage of total Population by Age Group and Sex, in 2005-06 (Includes Corresponding Graph/Chart)
- Table 18: the US Prevalence of Stroke as a Percentage of total Population by Age Group and Sex, in 2005-06 (Includes Corresponding Graph/Chart)
- Statistics From Nchs and Nhlbi On ‘death Due to Cardiovascular Diseases'
- Table 19: Mortality Rate in the US for the Year 2006 by Cardiovascular Diseases -Percentage Breakdown of Deaths From Coronary Heart Disease, Stroke, High Blood Pressure, Heart Failure, Diseases of the Arteries, and Others (Includes Corresponding Graph/Chart)
- Table 20: Mortality Rate in the US Males for the Year 2005 by Ailment - Heart Diseases, Cancer, Accidents, Chronic Lower Respiratory Diseases, and Diabetes (Includes Corresponding Graph/Chart)
- Table 21: Mortality Rate in the US Females for the Year 2005 by Ailment - Heart Diseases, Cancer, Chronic Lower Respiratory Diseases, Alzheimer's, and Accidents (Includes Corresponding Graph/Chart)
- Fall in Number of Deaths Due to Heart Diseases & Strokes
- Senior Citizens At High Risk for Heart Failure
- Baby Boomers Boost Coronary Stent Market
- Generics Trigger Price War
- Table 22: US Cardiovascular Drugs Market – total Prescriptions by Drug Class (In Thousands) for the Years 2008 and 2009 (Includes Corresponding Graph/Chart)
- Table 23: Select Leading Myocardial infarction Drugs in the Us: Value Sales in Us$ Million for the Years 2007 and 2008 (Includes Corresponding Graph/Chart)
- Table 24: Select Leading Coronary Artery Disease/ Atherosclerosis Drugs in the Us: Value Sales in Us$ Million for the Years 2007 and 2008 (Includes Corresponding Graph/Chart)
- Table 25: Select Leading Angina Drugs in the Us: Value Sales in Us$ Million for the Years 2007 and 2008 (Includes Corresponding Graph/Chart)
- Antihyperlipidemics
- Table 26: US Cardiovascular Drugs Market for Statins (Hmg Coa-Reductase inhibitors) – Type of Statin Ranked by Value Sales in Us$ Million for the Year 2007 (Includes Corresponding Graph/Chart)
- Table 27: US Antihyperlipidemic Drugs Market (2007): Percentage Share Breakdown of total Prescriptions by Leading Drugs (Includes Corresponding Graph/Chart)
- Anticoagulants and Antiplatelets
- Table 28: US Anticoagulant Drugs Market (2007): Percentage Share Breakdown of total Prescriptions by Leading Product (Includes Corresponding Graph/Chart)
- Drug Development Pipeline
- Us Pharmaceutical Sector Scenario
- Table 29: US Pharmaceutical Market (2008) – Leading Pharmaceutical Companies Ranked by Value Sales in Us$ Million (Includes Corresponding Graph/Chart)
- Table 30: US Pharmaceutical Market (2007) - Leading Pharmaceutical Products Ranked by Value Sales in Us$ Million (Includes Corresponding Graph/Chart)
- Table 31: US Pharmaceuticals Market (2008) - Leading therapeutic Class Ranked by Value Sales in Us$ Million (Includes Corresponding Graph/Chart)
- Table 32: US Cardiovascular Drugs Market (2008) - Leading Companies Ranked by Cardiovascular Drug Sales in Us$ Million (Includes Corresponding Graph/Chart)
- Canada
- Leading Drugs in Canada
- Table 33: Leading Prescription Drugs in Canada (2006 & 2007) - Number of Dispensed Prescriptions in Million Scripts for Lipitor, Synthroid, Norvasc, asaphen, Pantoloc, Crestor, Altace, Ratio-Salbutamol Hfa (Includes Corresponding Graph/Chart)
- Europe
- European Cardiovascular Diseases Fact Sheet
- Cardiovascular Disease – Risk Factor Profile
- The Cardiovascular Disease Cost Burden
- Mortality by Heart Attack Declines
- Eu to Face Health Care Expenditure Challenge Head-On
- 4.Product Launches/Approvals/ Developments
- Fda Approves Prasugrel
- Efient® (Prasugrel) Obtains Approval by European Commission
- The Medicines Company Obtains Approval for Angiox® by European Union
- Cv therapeutics Obtains Fda Approval for New indication for Ranexa
- Bms and Pfizer Announce Appraise-1 Results for Apixaban
- Scottish Medicines Consortium issues Approval for Various Drugs
- Schweizerhall Holding Ag/Cimex Ag to Launch Plavix® (Clopidogrel) Generic
- Response Bags Fda Clearance for Ramp® Nt-Probnp Test
- Plavix® Receives Fda Nod
- Sanofi-Aventis Wins Fda Approval to Use Lovenox in Stemi Patients
- Glaxosmithkline Receives Fda Approval for Arixtra injection
- Glaxosmithkline Wins Emea Approval for Arixtra
- Glaxosmithkline Wins Mhlw Approval for Arixtra
- Ranbaxy introduces Pravastatin Sodium 80mg Tablets in the US
- Glaxosmithkline introduces Coreg Cr™
- 5.Recent industry Activity
- Pfizer Acquires Wyeth
- Sanofi-Aventis Mexico Takes Over Laboratorios Kendrick
- Arca Biopharma Merges with Nuvelo
- Merck Merges Business with Schering-Plough
- Portola Pharmaceuticals Enters into Partnership with Novartis
- Richter-Helm Signs Agreement with Athera Biotechnologies
- Daiichi Sankyo Sets Up Subsidiary
- Zydus Cadila Joins forces with Eli Lilly for Cardiovascular Drug Research
- Atcor Medical Enters into Contract with Pharmaceutical Company
- Takeda Acquires Millenium Pharmaceuticals
- Daiichi- Sankyo Acquires Controlling Stake in Ranbaxy
- Glaxosmithkline Acquires Bristol Myers Squibb's Egyptian Business
- Shionogi Acquires Sciele Pharma
- Glaxosmithkline Acquires Reliant Pharmaceuticals
- Recordati Acquires Yeni Ilac
- China Sky One to Take Over Heilongjiang Tianlong Pharmaceutical
- King Pharmaceuticals to Acquire Alpharma
- Glaxosmithkline to Acquire Bristol-Myers Squibb Pakistan
- Meda Signs Deal to Take Over Roche Pharmaceutical Products
- Belupo and Farmavita Announce Merger
- Iroko Acquires Aggrastat's Rights From Merck
- Biological E Collaborates with Choncept and Heparinex
- Merck Serono Signs Distribution Agreement with Bristol-Myers Squibb
- Bms and Kai Sign Pact to Develop, Commercialize Cardiovascular Drug
- Cv therapeutics and Menarini Group Sign Deal for Ranexa
- forest Labs and Daiichi Sankyo Terminate Azor Co-Promotion Agreement
- Daiichi Sankyo Submits Application for Antihypertensive Drug Approval
- Daiichi Sankyo Establishes Subsidiary in Ireland
- Paion Announces Acquisition of Global Rights to Trigen's Flovagatran
- Cardiovascular Systems Merges with Replidyne
- Amic Recieves Non-Exclusive License From Roche Diagnostics
- Iroko Pharmaceuticals Wins Rights to Aggrastat®
- Sepracor Acquires Oryx Pharmaceuticals
- Gsk Acquires Reliant Pharmaceuticals
- Schering-Plough Takes Over Organon Biosciences
- Merck Serono and Bristol-Myers Squibb ink Latin American Distribution Deal
- Merck Acquires Novacardia
- Bristol-Myers and Pfizer ink Development and Commercialization Agreements
- Inverness Acquires Biosite
- Siemens Acquires Diagnostic Division of Bayer Healthcare
- Siemens Announces Acquisition of Dade Behring
- Inverness Acquires Cholestech
- Sanofi-Aventis Acquires Rights for Panaldine From Daiichi Sankyo
- Corautus Genetics and Via Pharmaceuticals Sign Merger Agreement
- Alchemia inks Marketing Alliance with Dr. Reddy's for Heparin
- Recordati- Berlin Chemie Expand Licensing Agreement
- 6.Focus On Select Global Players
- Abbott Laboratories inc. (Us)
- Astrazeneca (Uk)
- Bayer Ag (Germany)
- Boehringer ingelheim Gmbh (Germany)
- Bristol-Myers Squibb Company (Us)
- Daiichi Sankyo Company Limited (Japan)
- Dr. Reddy's Laboratories Ltd. (India)
- Eli Lilly and Company (Us)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Glaxosmithkline Plc (Uk)
- Inverness Medical innovations, inc. (Us)
- Merck & Co., inc. (Us)
- Medicure inc. (Canada)
- Novartis Ag (Switzerland)
- Pfizer, inc. (Us)
- Wyeth (Us)
- Sanofi-Aventis Sa (France)
- Schering-Plough Corp. (Us)
- Siemens Healthcare Diagnostics, inc. (Us)
- Takeda Pharmaceutical Company Limited (Japan)
- The Medicines Company (Us)
- III. Competitive Landscape
- Total Companies Profiled: 60 (Including Divisions/Subsidiaries - 73)
- Region/Countryplayers
- The United States34
- Canada
- Japan
- Europe
- France
- Germany
- The United Kingdom
- Italy
- Rest of Europe
- Asia-Pacific (Excluding Japan)
- Latin America